Acurx Pharmaceuticals, Inc.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a publicly held, clinical-stage biopharmaceutical company focused on developing a new class of antibiotics for infections caused by priority pathogens identified by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.

Products & Services

Ibezapolstat:A product in the pipeline, likely an antibiotic for specific infections (details not specified in content).

GPSS(r):A product in the pipeline, specifics not provided in the content.

Ibezapolstat

GPSS

Specialties

Development of new antibiotics Treatment of infections caused by priority pathogens Antibiotics for priority pathogens

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2500000 MR: - FA: Up to $7.1 million, with $2.5 million upfront and potential additional $4.6 million from warrants FAN: 2500000	D: 2026-04-16 FD: 2026-04-16	1 investors
2	RT: Grant T: - FT: Grant	A: 375000 MR: - FA: approximately $375,000 USD FAN: 375000	D: 2025-11-18 FD: 2025-11-18	1 investors
3	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2670000 MR: - FA: approximately $2.67 million FAN: 2670000	D: 2025-06-17 FD: 2025-06-17	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1100000 MR: - FA: approximately $1.1 million FAN: 1100000	D: 2025-03-10 FD: 2025-03-10	-
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1100000 MR: - FA: $1.1 million FAN: 1100000	D: 2025-03-07 FD: 2025-03-07	-
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2500000 MR: - FA: $2.5 million FAN: 2500000	D: 2025-01-07 FD: 2025-01-07	-
7	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2500000 MR: - FA: $2.5 Million FAN: 2500000	D: 2025-01-06 FD: 2025-01-06	1 investors
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4000000 MR: - FA: 4.0 million FAN: 4000000	D: 2023-05-16 FD: 2023-05-16	1 investors

Registered Direct Offering Latest

2026-04-16

$2.5M

1 investor (Pro only)

Grant 2025-11-18

$375K

Warrant Exercise 2025-06-17

$2.7M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David P. Luci

President and Chief Executive Officer

R

Robert J. DeLuccia

Executive Chairman

R

Robert G. Shawah

Co-Founder & Chief Financial Officer

M

Michael Silverman

Medical Director

L

Les Johnson

Manufacturing Director

X

Xiang Yu

Director of Pre-Clinical Development

View 20 more team members with Pro

Unlock Full Team Directory

Recent News